Search

everythinglearnresearchcommunity

for

Search:↓

The letter suggests testosterone replacement therapy might worsen COVID-19 outcomes.

Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.

Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.

Transgender patients on hormone therapy experience more acne and hair loss, but less skin inflammation.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

Male and female bodies respond differently to stress, influenced by hormones and development stages, with implications for stress-related diseases.

Hormone treatments in transsexual individuals reduce hair growth and oil production in male-to-females and increase them in female-to-males.

Hair loss needs more research for better treatments.

Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.

Hormonal treatments, including birth control and antiandrogens, can effectively treat acne in women.

Lower SHBG levels may increase the risk of PCOS.

Genetics and hormones play a role in male and female hair loss, but more research is needed to fully understand it.

Hormonal treatments can help with acne but are not the first choice due to side effects and the need for careful patient selection.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

Women with PCOS who have low SHBG are more likely to have low good cholesterol and metabolic syndrome.

Low-level laser therapy is safe and can increase hair growth for male and female pattern hair loss.

SHBG may be a useful early indicator and treatment target for PCOS.

Minoxidil helps hair growth and reduces shedding in women.

Finasteride helps reduce heart issues and improves heart function.

Minoxidil helps lower high blood pressure in kids, but can cause fluid retention and hair growth.

The document concludes that future heart disease research should account for sex-specific differences to improve diagnosis, treatment, and outcomes.

Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.

Testosterone therapy can help improve sexual desire and function in postmenopausal women but may cause side effects and is not FDA-approved for this use.

Using patients' own fat-derived cells to treat alopecia areata significantly improved hair growth and was safe.

Combination drug therapy is effective for hirsutism that doesn't improve with just one medication.

Sex hormones may affect COVID-19 severity, with men often faring worse, and targeting related pathways could offer treatment options.

Young women with diffuse hair loss may have low SHBG levels, which could lead to more active testosterone and contribute to their hair loss.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

The document concludes that treating PCOS requires a combination of drugs to manage reproductive and metabolic symptoms, with more research needed on combination therapies.